Candida auris, a multidrug-resistant fungal pathogen, presents an ongoing challenge to infection control in healthcare settings due to its ability to persist in the environment and resist common antifungal treatments. While transmission has been documented in hospitals and long-term care facilities, data on containment in dialysis settings remain limited.
Between 2020 and 2023, six patients infected or colonized with C auris received dialysis at five outpatient facilities across four states, New Jersey, North Carolina, South Carolina, and Tennessee, for up to four months. Notably, five of the facilities were unaware of the patients' C auris status during treatment and applied only standard dialysis infection prevention and control (IPC) measures. Among 174 potentially exposed contacts, only one additional patient with previously known colonization was identified, with no new transmissions detected.
To better understand these findings and their implications for practice, Contagion spoke with Alexandra Kurutz, MPH, an epidemiologist at the Tennessee Department of Health specializing in dialysis-related infection prevention, and Simone Godwin, DVM, MPH, MS, CIC, also an epidemiologist at the Tennessee Department of Health. They discussed IPC protocol effectiveness, communication breakdowns, and the role of targeted screening in outpatient dialysis settings.
Contagion: Were you surprised that standard IPC alone appeared sufficient to prevent C auris transmission in these cases?
Kurutz and Godwin: This outcome is one we considered given that standard dialysis IPC practices go beyond the usual precautions a healthcare facility would follow. Dialysis facilities already use bleach solutions as their primary disinfectant, which we know to be effective against C auris, and elements of personal protective equipment (PPE) are used and changed for each patient as a standard. Patients also typically receive dialysis on an outpatient basis and are only present in the facility a few hours, which equates to less time exposed compared to patients admitted to a hospital or residents of a nursing home for extended periods of time. There are some additional risks of infection with dialysis treatment such as an immune-compromised patient population and the access of indwelling devices, but we felt the standard dialysis IPC practices already address many of those risks. This is not to say additional precautions shouldn’t be taken with this and other particularly vulnerable patient populations, just that the baseline practices are already more extensive than in other settings.